Exelixis, Inc.
EXEL
Xếp hạng trong cổ phiếu
#1380
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Giá cổ phiếu
$64.01
Vốn hóa thị trường
$16.09B
Thay đổi (1 ngày)
2.11%
Thay đổi (1 năm)
85.31%
Quốc gia
US
Giao dịch Exelixis, Inc. (EXEL)
Danh mục
Healthcare
Thu nhập của Exelixis, Inc. (EXEL)
Thu nhập trong Jul 2026 TTM: $1.04B
Theo báo cáo tài chính gần đây của Exelixis, Inc., lợi nhuận hiện tại của công ty là $1.04B. Năm 2025, công ty đạt được lợi nhuận là $681.64M, tăng so với lợi nhuận năm 2023 là $257.52M. Lợi nhuận hiển thị trên trang này là lợi nhuận trước lãi vay và thuế, hay còn gọi là EBIT.
Lịch sử thu nhập của Exelixis, Inc. từ 2000 đến 2026
Thu nhập vào cuối mỗi năm
| Năm | Thu nhập | Thay đổi |
|---|---|---|
| 2026 (TTM) | $1.04B | 51.91% |
| 2025 | $681.64M | 164.69% |
| 2023 | $257.52M | 9.89% |
| 2022 | $234.35M | -20.33% |
| 2021 | $294.15M | 124.82% |
| 2020 | $130.84M | -67.14% |
| 2019 | $398.11M | -11.94% |
| 2018 | $452.09M | 185.09% |
| 2017 | $158.58M | -325.82% |
| 2016 | $-70.22M | -58.62% |
| 2015 | $-169.68M | -36.86% |
| 2014 | $-268.72M | 9.75% |
| 2013 | $-244.86M | 65.96% |
| 2012 | $-147.54M | -291.63% |
| 2011 | $76.99M | -183.32% |
| 2010 | $-92.40M | -34.39% |
| 2009 | $-140.84M | -13.52% |
| 2008 | $-162.85M | 88.53% |
| 2007 | $-86.38M | -14.89% |
| 2006 | $-101.49M | 7.05% |
| 2005 | $-94.81M | -30.92% |
| 2004 | $-137.25M | 44.29% |
| 2003 | $-95.12M | 12.52% |
| 2002 | $-84.53M | -0.17% |
| 2001 | $-84.68M | 4.59% |
| 2000 | $-80.96M | 0.00% |
Thu nhập của các công ty hoặc đối thủ tương tự
| Công ty | Thu nhập | Chênh lệch thu nhập | Quốc gia |
|---|---|---|---|
| $5.27B | 409.42% |
US
|
|
| $-3.09B | -398.13% |
US
|
|
| $-4.02B | -487.86% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 88.38% |
NL
|
